Psoriasis
Conditions
Brief summary
12 weeks DUOBRII to patients with 2%-10% BSA who are receiving biologic therapy for at least 24 weeks
Detailed description
A single center, pilot study of 25 subjects to assess 12 weeks DUOBRII to patients with 2%-10% body surface area who are receiving biologic therapy for at least 24 weeks
Interventions
DRUGDuobrii
duobrii applied daily for 4 weeks followed by every other day for 4 weeks.
Sponsors
Ortho Dermatologics
Psoriasis Treatment Center of Central New Jersey
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Intervention model description
open label
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Male or female adult ≥ 18 years of age; 2. Diagnosis of chronic plaque-type 3. Psoriasis affecting 2%-10% BSA 4. Patient is being treated with biologic therapy for a minimum of 24 weeks 5. Able and willing to give written informed consent prior to performance of any study-related procedures
Exclusion criteria
1. Psoriasis affecting ˂2% or \>10% BSA 2. Patient not receiving a biologic agent, or receiving biologic agent \<24weeks 3. Received treatment with any topical antipsoriatic drug product within 14 days prior to the Baseline visit. 4. Has previously used DUOBRII
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Body surface area improvement | 8 weeks | body surface area determined by palm method where 1 palm is equivalent to 1% |
Countries
United States
Contacts
Primary ContactJerry Bagel, MD
Backup ContactElise Nelson
Outcome results
None listed